Spekle Solutions specializes in shaping market access and commercial strategies for life sciences. The company uses advanced analytical techniques and technology to provide customized solutions and insights.

Spekle Solutions

Biocartis Group NV, a molecular diagnostics company, provides diagnostic solutions enhancing clinical practice for the benefit of patients, clinicians, payers, and healthcare industry with a focus on oncology. Its proprietary molecular diagnostics Idylla platform is a real-time polymerase chain reaction system that offers molecular information that allows treatment selection and treatment progress monitoring. The company offers Idylla BRAF, KRAS, MSI, EGFR, and NRAS-BRAF mutation tests; and Idylla SARS-CoV-2/Flu/RSV panels and SARS-CoV-2 tests, as well as SeptiCyte RAPID, a rapid host-response test. It also provides research products, including MSI, KRAS, BRAF, ctEGFR, NRAS-BRAF-EGFR S492R, ctKRAS, EGFR, GeneFusion, ctBRAF, and ctNRAS-BRAF-EGFR S492R mutation assays. The company has a collaboration agreement with Amgen to evaluate Idylla RAS testing as a tool for rapid decentralized testing and/or to accelerate access to RAS biomarker information using Idylla platform and RAS tests; and Bristol-Myers Squibb Company for the registration of diagnostic and use of the Idylla MSI test in connection with immuno-oncology therapies. It also has a license, development, and commercialization agreement with GeneproDx for the development of ThyroidPrint novel genomic test on the Idylla platform. The company was founded in 2007 and is headquartered in Mechelen, Belgium.

Biocartis Group NV

DxTerity is a company that specializes in RNA testing, providing a more complete and dynamic picture of disease status. Their patented and proprietary innovations aim to bring low-cost, precision testing to an underserved community, improving access to care and increasing healthcare equity.

Bob Terbrueggen

DxTerity

Foundation Medicine, Inc. develops, manufactures, and sells genomic profiling assays based on next-generation sequencing technology for solid tumors, hematologic malignancies, and sarcomas.

Metric
Company Name	Spekle Solutions	Biocartis Group NV	DxTerity	Foundation Medicine, Inc.
Symbol		BCART
MSH ID	COM:SPEKLESOLUTIONS	COM:BIOCARTIS	COM:DXTERITY	COM:FOUNDATIONMEDICINE
Market	PRIVATE	STOCKS	PRIVATE	PRIVATE
Sector	Commercial & Professional Services	Healthcare	Healthcare & Health Services	Healthcare & Health Services
Industry	Consulting	Medical - Diagnostics & Research	Healthcare & Health Services	Biotechnology
Country	US	BE		US
Stage				Series B
Employee Count		526	11	1.84K
Website	speklesolutions.com	biocartis.com	dxterity.com	foundationmedicine.com
LinkedIn				foundation-medicine
Founders

Metric
Market Cap	28.77M
Enterprise Value
Monthly Web Traffic		40.74K
Web Traffic Growth		-0.28
Valuation
Raised Capital		13.50M

Metric
Revenue		60.71M
Revenue (LTM)
Revenue (NTM)
Gross Profit		29.24M
EBITDA		-46.11M
Operating Income		-49.38M
Net Income		-69.06M
EPS		-1.14
Diluted EPS		-1.14
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin		0.32
Operating Profit Margin		-0.71
EBITDA Margin		-0.76
Net Profit Margin		-1.11
Return on Equity		1.81
Return on Assets		-0.74
Return on Capital Employed		-0.67

SPEK

COM:SPEKLESOLUTIONS

Spekle Solutions

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio		-0.27
P/B Ratio		-0.58
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio		0.36
EV Multiple		2.43

Metric
Days Sales Outstanding		165.75
Days Payables Outstanding		143.89
Days Inventory Outstanding		127.62
Operating Cycle		238.75
Cash Conversion Cycle		189.50
Asset Turnover		0.81

Metric
Operating Cash Flow		-47.38M
Free Cash Flow		-49.42M
Cash Flow to Debt		-0.42
Operating Cash Flow/Sales		-0.82
Free Cash Flow Yield		-1.72

Metric
Cash & Equivalents		26.33M
Accounts Receivable		1.67M
Inventory		19.97M
Goodwill
Debt to Capitalization		1.55
Debt to Assets		1.07
Current Ratio		1.65
Quick Ratio		1.49

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue		0.01
R&D to Revenue		0.67
SG&A to Revenue		0.06